Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders for Matinas Biopharma Holdings, Inc., held on October 25, 2017. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Election of Directors: Six individuals were elected to the Board of Directors to serve until the 2018 annual meeting. All candidates received significant majority support, with "For" votes ranging from approximately 24.3 million to 24.8 million. "Withheld" votes were minimal (ranging from 40,861 to 571,398). There were 27,694,436 broker non-votes for each director election.
- Ratification of Auditors: Stockholders approved the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017. The vote tally was 51,796,081 "For," 778,510 "Against," and 400 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the election of Herbert Conrad, Roelof Rongen, Eric Ende, Stefano Ferrari, Adam Stern, and James Scibetta.
- Confirm the engagement of EisnerAmper LLP as the independent auditor for the fiscal year ending December 31, 2017.
- Review the definitive proxy statement filed on September 14, 2017, for detailed biographies of directors and further context on the proposals.